Authors : Friery OP; Radiation Science Research Group, School of Biomedical Sciences, University of Ulster at Jordanstown, Antrim, Northern Ireland, UK.; Gallagher R

Subjects: Anthraquinones/Anthraquinones/Anthraquinones/*therapeutic use ; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use

Source: British journal of cancer [Br J Cancer] 2000 Apr; Vol. 82 (8), pp. 1469-73.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print Cited Medium:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin

Authors : Kovacs, MS; Hocking, DJ; Evans, JW

Subjects: Biomedical and Clinical Sciences; Clinical Sciences; 2.1 Biological and endogenous factors

Source: British Journal of Cancer. 80(8)

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy.

Authors : Garrett CR; Department of Gastrointestinal Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA. ; Siu LL

Subjects: Salvage Therapy*; Alanine/Alanine/Alanine/*analogs & derivatives ; Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*pharmacokinetics

Source: British journal of cancer [Br J Cancer] 2011 Jun 28; Vol. 105 (1), pp. 44-52. Date of Electronic Publication: 2011 May 31.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.

Authors : D'Amato V; 1] Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli 'Federico II', Naples, Italy [2] IRCCS Multimedica-Bioker, Milano, Italy.; Rosa R

Subjects: Phosphoinositide-3 Kinase Inhibitors*; Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/*pharmacology ; Carcinoma, Squamous Cell/Carcinoma, Squamous Cell/Carcinoma, Squamous Cell/*drug therapy

Source: British journal of cancer [Br J Cancer] 2014 Jun 10; Vol. 110 (12), pp. 2887-95. Date of Electronic Publication: 2014 May 13.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N.

Authors : Gallagher R; Radiation Science Research Group, School of Biomedical Sciences, University of Ulster at Jordanstown, Newtownabbey, Co. Antrim, Northern Ireland BT37 0QB.; Hughes CM

Subjects: Anthraquinones/Anthraquinones/Anthraquinones/*pharmacology ; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacology ; Cisplatin/Cisplatin/Cisplatin/*pharmacology

Source: British journal of cancer [Br J Cancer] 2001 Aug 17; Vol. 85 (4), pp. 625-9.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print Cited Medium:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Targeting EGFR and PI3K pathways in ovarian cancer.

Authors : Glaysher S; Translational Oncology Research Centre, Queen Alexandra Hospital, Portsmouth PO6 3LY, UK.; Bolton LM

Subjects: Phosphoinositide-3 Kinase Inhibitors*; ErbB Receptors/ErbB Receptors/ErbB Receptors/*antagonists & inhibitors ; Ovarian Neoplasms/Ovarian Neoplasms/Ovarian Neoplasms/*drug therapy

Source: British journal of cancer [Br J Cancer] 2013 Oct 01; Vol. 109 (7), pp. 1786-94. Date of Electronic Publication: 2013 Sep 10.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation.

Authors : Loriot Y; Institut Gustave Roussy, UPRES 27-10, 39 rue Camille Desmoulins, 94800 Villejuif, France.; Mordant P

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacology ; Carcinoma, Non-Small-Cell Lung/Carcinoma, Non-Small-Cell Lung/Carcinoma, Non-Small-Cell Lung/*drug therapy ; ErbB Receptors/ErbB Receptors/ErbB Receptors/*antagonists & inhibitors

Source: British journal of cancer [Br J Cancer] 2010 Jul 27; Vol. 103 (3), pp. 347-53. Date of Electronic Publication: 2010 Jul 13.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy.

Authors : Lunt SJ; School of Pharmacy and Pharmaceutical Sciences, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK.; Cawthorne C

Subjects: Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Cell Hypoxia/Cell Hypoxia/Cell Hypoxia/*drug effects ; Imidazoles/Imidazoles/Imidazoles/*administration & dosage

Source: British journal of cancer [Br J Cancer] 2010 Jul 13; Vol. 103 (2), pp. 201-8. Date of Electronic Publication: 2010 Jun 29.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.

Authors : Saunders MP; Department of Pharmacy and Pharmaceutical Sciences, University of Manchester, UK.; Patterson AV

Subjects: Cell Hypoxia*; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacokinetics ; Lung Neoplasms/Lung Neoplasms/Lung Neoplasms/*pathology

Source: British journal of cancer [Br J Cancer] 2000 Feb; Vol. 82 (3), pp. 651-6.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print Cited Medium:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.

Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine.

Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy.

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.

The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N.

Targeting EGFR and PI3K pathways in ovarian cancer.

BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation.

The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy.

NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.

اتصل بنا

اتبع